Research programme: CNS therapeutics - Ossianix

Drug Profile

Research programme: CNS therapeutics - Ossianix

Alternative Names: Anti-CD20/TfR1 bispecific antibodies

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Ossianix
  • Class Analgesics; Antibodies; Bispecific antibodies
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research CNS disorders; Pain

Most Recent Events

  • 01 Apr 2017 Early research is ongoing for CNS disorders in USA
  • 01 Apr 2017 Preclinical data in CNS disorders presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top